Patient selection for neoadjuvant therapy in early-stage pancreatic cancer

Journal of Clinical Oncology

Volumn 35, Issue 14, 2017, Pages 1622-1623

  Bergquist, John R ^a   Shubert, Christopher R ^a   Storlie, Curtis B ^a   Habermann, Elizabeth B ^a   Truty, Mark J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; NEOADJUVANT THERAPY; PANCREAS; PANCREAS TUMOR; PATIENT SELECTION; PROPENSITY SCORE;

HUMANS; NEOADJUVANT THERAPY; PANCREAS; PANCREATIC NEOPLASMS; PATIENT SELECTION; PROPENSITY SCORE;

EID: 85019061799     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.71.2315     Document Type: Letter

References (10)

1. Mokdad AA, Minter RM, Zhu H, et al: Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: A propensity score matched analysis. J Clin Oncol 35:515-522, 2015
2. Shubert CR, Bergquist JR, Groeschl RT, et al: Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database. Surgery 160: 1080-1096, 2016
3. Yovino S, Darwin P, Daly B, et al: Predicting unresectability in pancreatic cancer patients: The additive effects of CT and endoscopic ultrasound. J Gastrointest Surg 11:36-42, 2007
4. Bergquist JR, Puig CA, Shubert CR, et al: Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: A National Cancer Database study. J Am Coll Surg 223: 52-65, 2016
5. Katz MH, Varadhachary GR, Fleming JB, et al: Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol 17:1794-1801, 2010
6. Austin PC, Small DS: The use of bootstrapping when using propensity-score matching without replacement: A simulation study. Stat Med 33:4306-4319, 2014
7. Wiedermann CJ, Wiedermann W: Propensity matching cannot substitute for randomization in albumin studies. Crit Care 19:206, 2015
8. Day AG: Why the propensity for propensity scores? Crit Care Med 43: 2024-2026, 2015
9. Galsky MD, Stensland KD, Moshier E, et al: Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J Clin Oncol 34:825-832, 2016
10. Bang H, Robins JM: Doubly robust estimation in missing data and causal inference models. Biometrics 61:962-973, 2005